Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for  in vivo tumor-targeted drug delivery

Taghavi, Sahar; Ramezani, Mohammad; Alibolandi, Mona; Abnous, Khalil; Taghdisi, Seyed Mohammad

doi:10.1016/j.canlet.2017.04.008

Cited by 122 publications

(39 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RNA aptamer against CD133 showed high selectivity against HT29 cells. In this regard, the versatility of MUC1, AS1411, and EpCAM conjugated NPs against AGS, HT29, and MCF-7 cell lines was previously reported and the obtained results verified the enhanced cytotoxicity and uptake of aptamer-targeted systems in comparison with nontargeted ones [34][35][36][37][38].…”

Section: Mtt Assaysupporting

confidence: 75%

CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer

Alibolandi

Abnous

Anvari

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

Poor aqueous solubility of chemotherapeutics such as SN38 (7-ethyl-10-hydroxycamptothecin) and the associated systemic adverse effects are serious limitations of their clinical use. To improve the drug delivery efficiency of such compounds, they were covalently conjugated to hydrophilic macromolecular carriers that specifically deliver the drug moiety to the tumour cells. In the current study, we developed a PEGylated acetylated carboxymethylcellulose conjugate of SN38 which was covalently attached to an aptamer against a cancer stem cell marker, CD133. Then, the designed nanoplatform was used to specifically deliver SN38 to colorectal cancer cells. The results demonstrated that the synthesized conjugate was self-assembled to nanoparticles with 169 nm in size and poly dispersity index of 0.11. Besides, the targeted self-assembled nanoparticles could significantly enhance the cellular uptake by CD133-expressing HT29 cell line confirmed by fluorescent microscopy and flow cytometry. Moreover, our results revealed that the targeted self-assembled nanoconjugate exhibited significantly lower IC in HT29 cells overexpressing CD133 compared to non-targeted self-assembled nanoconjugate. The promising data suggest that the prepared targeted self-assembled drug conjugate nanoparticles possess the potential to offer the desirable physicochemical properties thereby enhancing the solubility and the therapeutic index of poorly soluble cytotoxic agents.

show abstract

Section: Mtt Assaysupporting

confidence: 75%

CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer

Alibolandi

Abnous

Anvari

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The suspension was freeze centrifuged (2-16KL, Sigma Laborzentrifugen GmbH, Osterode am Harz, Germany) and the obtained NPs were washed with distilled water and kept in the refrigerator at°C for further studies. [17][18][19] Characterization of AT-PLGA-CS-NPs Particle size, particle distribution, and the surface charge of formed NPs were quantized on a Zetasizer Nano ZS90 (Malvern Instruments Ltd., Malvern, UK). AT-PLGA-CS-NP morphology was inspected by transmission electron microscopy (TEM; H-600, Hitachi, Tokyo, Japan).…”

Section: Preparation Of At-plga-cs-npsmentioning

confidence: 99%

<p>Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium</p>

Arafa¹,

Girgis²,

El-Dahan³

2020

IJN

View full text Add to dashboard Cite

Background: Atorvastatin calcium (AT) is an ocular anti-inflammatory with limited bioavailability when taken orally due to its low solubility in low pH and extensive first-pass effect. To overcome these problems, AT was entrapped in polymeric nanoparticles (NPs) to improve surface properties and sustained release, in addition to achieving site-specific action. Methods: AT was entrapped in chitosan (CS)-coated polylactic-co-glycolic acid (PLGA) NPs to form AT-PLGA-CS-NPs (F1). F1 and free AT were embedded in thermosensitive Pluronic ® 127-hydroxypropyl methylcellulose (HPMC) to form thermosensitive gels (F2) and (F3) while F4 is AT suspension in water. F1 was assessed for size, surface charge, polydispersity index (PDI), and morphology. F2 and F3 were examined for gelation temperature, gel strength, pH, and viscosity. In vitro release of the four formulations was also investigated. The ocular irritancy and anti-inflammatory efficacy of formulations against prostaglandin E 1-(PGE 1) induced ocular inflammation in rabbits were investigated by counting the polymorphonuclear leukocytes (PMNs) and protein migrated in tears. Results: Oval F1 of 80.0-190.0±21.6 nm exhibited a PDI of 0.331 and zeta potential of 17.4 ±5.62 mV with a positive surface charge. F2 and F3 gelation temperatures were 35.17±0.22°C and 36.93±0.31°C, viscosity 12,243±0.64 and 9759±0.22 cP, gel strength 15.56±0.6 and 12.45 ±0.1 s, and pHs of 7.4±0.02 and 7.4±0.1, respectively. In vitro release of F1, F2, F3, and F4 were 48.21±0.31, 26.48±0.5, 84.76±0.11, and 100% after 24 hrs, respectively. All formulations were non-irritant. F2 significantly inhibited lid closure up to 3 h, PMN counts and proteins in tear fluids up to 5 h compared to other formulations. Conclusion: AT-PLGA-CS-NP thermosensitive gels proved to be successful ocular antiinflammatory drug delivery systems.

show abstract

“…Previously, it was shown that the chitosan coating is a successful approach for preparation of sustained release system of various cargos, increase cellular uptake of PLGA-based NPs and finally enhance therapeutic index [9,10].…”

Section: Preparation and Characterization Of Nanoparticlesmentioning

confidence: 99%

“…One of the emerging targets for drug delivery is the Avb3integrin expressed on the surface of endothelial cells and vascular smooth muscles which stimulation by thyroid hormones leading to induction of proliferation of tumour cells and angiogenesis [9].…”

Section: Introductionmentioning

confidence: 99%

Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38

Alibolandi

Farzad

Mohammadi

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

New integrin-targeted nanoparticles made of chitosan-stabilized PLGA matrix was developed to specifically target colon adenocarcinoma. To this aim, SN38-encapsulated chitosan-coated PLGA NPs were conjugated with tetrac for integrin receptor-guided delivery. To provide a sustained release pattern for SN38, it was loaded into nanoparticles using single emulsion method. The size of NPs were 174.23 ± 6.12 nm with drug encapsulation efficiency and loading content of 73.16 ± 11.15 and 4.45 ± 0.31, respectively. The in vitro results confirmed that the designed nanoplatform showed specific cellular uptake and cytotoxicity in integrin overexpressing cancer cells and provided a sustained release profile for SN38. Additionally, an increased therapeutic potency of targeted formulation over both non-targeted and free drug was shown in vivo.

show abstract

Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery

Cited by 122 publications

References 39 publications

CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer

CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer

<p>Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium</p>

Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38

Contact Info

Product

Resources

About